Buy Corlanor (Ivabradine) from Maple Leaf Medications.

Corlanor (ivabradine) Indications

Corlanor, generic name ivabradine, is typically prescribed to reduce the risk of hospitalization due to worsening heart failure in adults with symptomatic chronic heart failure with reduced ventricular ejection fraction.

Corlanor is also used to treat stable symptomatic heart failure caused by dilated cardiomyopathy among pediatric patients who are 6 months of age and above.

Corlanor is classified as a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker. This type of medication mainly works by regulating heart rate and prolonging diastolic time.

Corlanor (ivabradine) Uses and Dosage

You must read the prescription information leaflet before using Corlanor oral medication.

Take Corlanor medication exactly as advised by the doctor. This is typically taken two times a day (preferably at equal intervals) by mouth with food. Swallow the tablet and drink fluids right after. You may cut the scored tablets in equal halves.

The doctor may initiate this treatment at a low dose and carefully increase the dose in order to minimize the risk of side effects.

Corlanor (ivabradine) Side Effects

Side effects caused by Corlanor medication are typically mild. Here are the common side effects:

• Dizziness or lightheadedness
• High blood pressure
• Tiredness
• Slow heart rate or bradycardia
• Temporary vision disturbance, like seeing flashes of light

If any of the adverse effects above persist or worsen, you should consult your doctor about it.

Serious Side Effects

Some of the reported severe side effects of Corlanor are as follows:

• Irregular heartbeat or atrial fibrillation
• Fainting
• Unusual weakness or fatigue
• Continuous high blood pressure

These severe adverse effects must be relayed to your healthcare provider immediately.

Allergic Reactions

Do not administer Corlanor oral medication if you are allergic to ivabradine or any of this product’s ingredients. Allergic reactions have the potential to be severe. Seek emergency intervention if an allergy develops while using this prescription.

Signs of an allergy are:

• Swelling of the face and neck
• Hives
• Itching
• Rashes
• If severe, you may also experience:
  • Severe dizziness
  • Wheezing
  • Trouble breathing

Corlanor (ivabradine) Cautions

Corlanor is contraindicated in patients with:

• Acute decompensated heart failure
• Irregular heartbeat
• Pacemaker
• Sick sinus syndrome
• Heart block
• Low blood pressure
• Liver problems

Corlanor should be avoided by women who are pregnant or are planning to conceive. This medication may harm or cause undesirable effects to unborn babies.

Ivabradine is known to pass into breast milk and should be avoided in breastfeeding women.

Corlanor (ivabradine) Form and Strength

Corlanor (brand) and ivabradine (generic) are available in the following forms and strengths:

• Corlanor, tablet
  • 5 mg
  • 5 mg
• Corlanor, oral solution
  • 5 mg/5 mL
• Ivabradine, tablet
  • 5 mg
  • 5 mg

FAQ

Is Corlanor a beta blocker?

Corlanor oral prescription is not a beta blocker. It is a hyperpolarization-activated cyclic nucleotide-gated channel blocker.

Does Corlanor work immediately?

It may take a short while for Corlanor oral medication to work. It may start working within two hours when taken with food.

What should I avoid while taking Corlanor?

While taking Corlanor medication do not consume grapefruit, or anything with grapefruit in it, as this fruit can increase the level of ivabradine in the body. Alcohol intake must also be limited because it can trigger certain side effects.

How much does Corlanor lower heart rate?

The dosage of Corlanor is primarily based on the patient’s targeted heart rate. In adults, this medication should reduce the heart rate to 50-60 beats per minute.

Resources

https://www.corlanor.com/

https://www.webmd.com/drugs/2/drug-168326/corlanor-oral/details

https://www.drugs.com/corlanor.html

https://www.rxlist.com/corlanor-side-effects-drug-center.htm

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209964lbl.pdf